Caption Management’s AbCellera Biologics ABCL Stock Holding History

Caption Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-151,000	Closed	-$1.53M	–	1036
2022 Q4	$1.53M	Buy	151,000 +1,000	+0.7%	+$11.6K	0.02%	630
2022 Q3	$1.48M	Sell	150,000 -150,000	-50%	-$1.65M	0.02%	738
2022 Q2	$3.19M	Hold	300,000	–	–	0.04%	514
2022 Q1	$2.92M	Buy	300,000 +80,000	+36%	+$757K	0.04%	610
2021 Q4	$3.15M	Hold	220,000	–	–	0.04%	623
2021 Q3	$4.41M	Buy	220,000 +150,000	+214%	+$2.65M	0.05%	498
2021 Q2	$1.54M	Buy	+70,000	New	+$1.93M	0.02%	778

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Caption Management's ABCL Position: Q1 2023 in Review

Caption Management sold out of AbCellera Biologics (ABCL) in Q1 2023, closing a stake of 88,332 shares — an estimated $895K sold.

Caption Management first reported a position in ABCL in Q2 2021 and held it in 5 quarters. The position peaked at $1.01M in Q4 2021. 183 funds tracked by Wall St. Rank hold ABCL as of Q1 2023.

Caption Management reported no remaining AbCellera Biologics position as of Q1 2023 after selling out during the quarter.
Caption Management sold 88,332 AbCellera Biologics shares in Q1 2023, an estimated $895K.
Caption Management first reported a position in AbCellera Biologics in Q2 2021 and held it in 5 quarters.
Caption Management's AbCellera Biologics position peaked at $1.01M in Q4 2021.
183 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2023.

Based on Caption Management's 13F filing for Q1 2023, filed 15 May 2023.